eMagin (EMAN) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for eMagin in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" EMAN shares.
View EMAN analyst ratings or view top-rated stocks.

1 brokerages have issued 12 month price targets for eMagin's shares. Their EMAN share price forecasts range from $3.00 to $3.00. On average, they predict the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 50.0% from the stock's current price.
View analysts price targets for EMAN or view top-rated stocks among Wall Street analysts.

eMagin's stock was trading at $0.8999 at the beginning of 2023. Since then, EMAN stock has increased by 122.2% and is now trading at $2.00.
View the best growth stocks for 2023 here.

eMagin saw a increase in short interest in May. As of May 15th, there was short interest totaling 3,340,000 shares, an increase of 10.2% from the April 30th total of 3,030,000 shares. Based on an average daily volume of 911,300 shares, the short-interest ratio is presently 3.7 days.
View eMagin's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our EMAN earnings forecast.

eMagin Co. (NYSEAMERICAN:EMAN) posted its quarterly earnings data on Thursday, March, 9th. The semiconductor company reported $0.01 earnings per share (EPS) for the quarter. The semiconductor company earned $8.39 million during the quarter. eMagin had a negative net margin of 12.05% and a negative trailing twelve-month return on equity of 17.74%.

Based on aggregate information from My MarketBeat watchlists, some companies that other eMagin investors own include Guyana Goldfields (GUY), Hawkins (HWKN), CA (CA), Kopin (KOPN), Universal Display (OLED), Ampio Pharmaceuticals (AMPE), OPKO Health (OPK), Riot Platforms (RIOT), BlackRock (BLK) and Advanced Micro Devices (AMD).

eMagin trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "EMAN."

eMagin's stock is owned by a number of institutional and retail investors. Top institutional investors include Geode Capital Management LLC (0.79%), Jane Street Group LLC (0.18%), Connor Clark & Lunn Investment Management Ltd. (0.04%), Charles Schwab Investment Management Inc. (0.04%), Blair William & Co. IL (0.04%) and Two Sigma Securities LLC (0.02%). Insiders that own company stock include Amalkumar Ghosh, Andrew George Sculley Jr, Eric Braddom, Joseph Saltarelli, Ltd Enervest, Ltd Ginola, Mark A Koch, Prache Olivier and Stillwater Holdings Llc.
View institutional ownership trends.

Shares of EMAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EMAN stock can currently be purchased for approximately $2.00.

eMagin (NYSEAMERICAN:EMAN) has a market capitalization of $166.08 million and generates $30.53 million in revenue each year. The semiconductor company earns $-1,100,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis.

The company employs 101 workers across the globe.

eMagin's mailing address is 2070 Route 52 Building 334, HOPEWELL JUNCTION, NY 12533-3507, United States. The official website for the company is www.emagin.com. The semiconductor company can be reached via phone at (845) 838-7900, via email at investorrelations@emagin.com, or via fax at 845-838-7901.